A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) Recipients With Bronchiolitis Obliterans Syndrome (BOS) Grade 1-2
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 03 May 2018
At a glance
- Drugs Nintedanib (Primary)
- Indications Bronchiolitis obliterans
- Focus Therapeutic Use
- Acronyms INFINITx-BOS
- 31 Aug 2018 Biomarkers information updated
- 26 Apr 2018 Planned End Date changed from 1 Nov 2021 to 1 May 2022.
- 26 Apr 2018 Planned primary completion date changed from 1 Apr 2021 to 1 Oct 2021.